Lu-Yang Li, Shinichiro Kobayashi, Shunsuke Murakami, Shun Yamaguchi, Kaito Tasaki, Susumu Eguchi, Kengo Kanetaka, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan
Author contributions: Li LY and Kobayashi S drafted the manuscript; Li LY, Kobayashi S, Murakami S, Yamaguchi S, and Tasaki K edited the manuscript; Eguchi S and Kanetaka K conceived the study and supervised the overall design. All authors have read and approved the final manuscript.
Supported by Japan Society for the Promotion of Science, No. 24K11935.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Shinichiro Kobayashi, MD, PhD, Associate Professor, FACS, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. skobayashi1980@gmail.com
Received: August 25, 2025 Revised: October 2, 2025 Accepted: November 3, 2025 Published online: January 27, 2026 Processing time: 151 Days and 2 Hours
Core Tip
Core Tip: The conventional tumor-node-metastasis (TNM) staging system for gastric cancer has limitations as it often fails to capture tumor biology and host immune responses. Zhou et al developed a novel composite biomarker using the inflammatory markers, systemic inflammation response index and platelet-to-lymphocyte ratio. This score has been identified as an independent predictor of survival. A nomogram integrating this score with the TNM stage and other factors demonstrated superior predictive accuracy compared with the TNM system alone. Although promising, these findings require multicenter validation. Future studies should integrate these biomarkers with genomic data for more precise and personalized risk stratification of patients with gastric cancer.
